Affiliation:
1. Chonnam National University
Abstract
Abstract
Safety is one of the important factors constraining the distribution of clinical drugs on the market. Drug-induced liver injury (DILI) is the leading cause of safety problems produced by drug side effects. Therefore, the DILI risk of approved drugs and potential drug candidates should be assessed. Currently, in vivo and in vitro methods are used to test DILI risk, but both methods are labor-intensive, time-consuming, and expensive. To overcome these problems, many in silico methods for DILI prediction have been suggested. Previous studies have shown that DILI prediction models can be utilized as prescreening tools, and they achieved a good performance. However, there are still limitations in interpreting the prediction results. Therefore, this study focused on interpreting the model prediction to analyze which features could potentially cause DILI. For this, five publicly available datasets were collected to train and test the model. Then, various machine learning methods were applied using structure and physicochemical features as inputs and the DILI label as the output. The interpretation of feature importance was analyzed by recognizing the following general-to-specific patterns: i) identifying general important features of the overall DILI predictions, and ii) highlighting specific molecular substructures which were highly related to the DILI prediction for each compound. The results indicated that the model not only captured the structure and physicochemical features previously known to be related to DILI but also proposed a new DILI potential molecular substructure. The models for the DILI prediction achieved an area under the receiver operating characteristic (AUROC) of 0.88 to 0.97 and an area under the Precision-Recall curve (AUPRC) of 0.81 to 0.95. From this, we hope the proposed models can help identify the potential DILI risk of drug candidates at an early stage and offer valuable insights for drug development.
Publisher
Research Square Platform LLC
Reference51 articles.
1. Drug-induced liver injury: present and future;Suk KT;Clin Mol Hepatol,2012
2. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States?;Vuppalanchi R;Am J Gastroenterol (Springer Nature),2007
3. Incidence of drug-induced hepatic injuries: a French population-based study;Sgro C;Hepatology,2002
4. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature;Onakpoya IJ;BMC Med,2016
5. Trends in clinical success rates and therapeutic focus;Dowden H;Nat Rev Drug Discov,2019